RAPP in the news
Precision, empathy, growth activation
Tamtam found 20 recent articles about RAPP.
- Analysts Conflicted on These NA Names: General Dynamics (GD), Rapport Therapeutics, Inc. (RAPP) and First Solar (FSLR)
Analysts are conflicted on General Dynamics, while maintaining Buy ratings for Rapport Therapeutics and First Solar.
- Market Movers | Winners: QNC, EGHT, FSLY | Losers: CGEM, ALKT, RAPP
This article analyzes market movers, providing lists of top-performing and underperforming US stocks daily, weekly, and monthly, and advises investigating businesses behind ticker symbols instead of chasing performance.
- Rapport Therapeutics (RAPP) officer flags $553K stock sale plan
A Rapport Therapeutics officer plans to sell over $553,000 worth of company stock.
- Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month High - Should You Buy?
Rapport Therapeutics' stock hit a new 52-week high, driven by positive analyst ratings despite insider selling and a recent earnings miss, as the biopharmaceutical company continues its focus on cancer therapies.
- Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan
Rapport Therapeutics CEO Abraham Ceesay sold 51,499 shares of the company's common stock in August 2026, executed via a pre-arranged trading plan.
- Omnicom moves Rapp into Critical Mass and global CEO exits in restructure
Omnicom is folding the agency Rapp into Critical Mass and its global CEO is stepping down following a division restructure.
- RAPP: RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing
RAPP is advancing its precision neuroscience candidate RAP-219 into phase III trials for focal epilepsy with upcoming clinical data for bipolar mania.
- Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144
Third Rock Ventures liquidated over $65 million worth of RAPP shares across three transactions in April and May 2026.
- (RAPP) Volatility Zones as Tactical Triggers
Institutional trading strategies use AI models and volatility zones to manage risk and optimize positions.
- Form 144 shows proposed 500-share sale; insider 10b5-1 trades (RAPP)
Morgan Stanley Smith Barney LLC filed Form 144 proposing a 500-share sale and disclosing Krishnaswamy's 10b5-1 dispositions.
- Form 144: Morgan Stanley Smith Barney (NASDAQ: RAPP) lists 360-share sale
Morgan Stanley Smith Barney lists a 360-share sale of RAPP shares.
- Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts
Rapport Therapeutics receives a "Moderate Buy" rating from analysts despite recent insider selling and missing earnings estimates.
- Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform?
Rapport Therapeutics is set to present trial data for its precision seizure drug RAP-219, with its investment value dependent on clinical progress and future funding.
- (RAPP) Risk Channels and Responsive Allocation
Rapport Therapeutics faces weak near- and mid-term sentiment with elevated downside risk and no clear price positioning signals, while AI-generated strategies aim to manage risk.
- How Rapport’s Greater China RAP-219 Licensing Deal At Rapport Therapeutics (RAPP) Has Changed Its Investment Story
Rapport Therapeutics' licensing deal for RAP-219 in Greater China injects funding and accelerates Phase 3 trials but does not eliminate clinical and financial risks.
- Rapp at Home receives grant to reduce risk of social isolation
Rapp at Home secured a $10,000 grant to fund programs reducing social isolation risks among older adults.
- Marketing Skills Trust, Ogilvy and Rapp to run mentorships in memory of ex-Ogilvy chief
A mentorship programme honoring ex-Ogilvy and Rapp CEO Mike Dodds and his wife Claire is launching to support early-career marketers.
- New Analyst Forecast: $RAPP Given $47 Price Target
Analysts have set varied price targets for RAPP stock, with recent insider selling and mixed institutional investor activity.
- Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)?
Rapport Therapeutics is set to reveal important Phase 2a trial data for RAP-219 in seizures, a key event that may impact its scientific and investment outlook amid financial risks.
- New Analyst Forecast: $RAPP Given $47.0 Price Target
Analysts have set varied price targets for RAPP stock, with recent insider selling and mixed institutional investor activity.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like RAPP?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies